1. ASRM . Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril 2017; 107: 43–51.
Google Scholar | Crossref | Medline2. Stenchever, MA. Risks of oral contraceptive use in women over 35. J Reprod Med 1993; 38: 1030–1035.
Google Scholar | Medline3. Curtis, KM, Tepper, NK, Jatlaoui, TC, et al. U.S. Medical eligibility criteria for contraceptive use, 29 July 2016.
Google Scholar4. Dinger, J, Bardenheuer, K, Heinemann, K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric 2016; 19: 349–356.
Google Scholar | Crossref | Medline5. Grodstein, F, Manson, JE, Colditz, GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933–941.
Google Scholar | Crossref | Medline6. Pickar, JH, Archer, DF, Kagan, R, et al. Safety and benefit considerations for menopausal hormone therapy. Expert Opin Drug Saf 2017; 16: 941–954.
Google Scholar | Crossref | Medline7. Harman, SM, Vittinghoff, E, Brinton, EA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med 2011; 124: 199–205.
Google Scholar | Crossref | Medline8. Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 2002; 288: 321–333.
Google Scholar | Crossref | Medline9. Allison, MA, Manson, JE, Langer, RD, et al. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women’s Health Initiative coronary artery calcium study. Menopause 2008; 15: 639–647.
Google Scholar | Crossref | Medline10. Giordano, S, Hage, FG, Xing, D, et al. Estrogen and cardiovascular disease: is timing everything? Am J Med Sci 2015; 350: 27–35.
Google Scholar | Crossref | Medline11. Stewart, M, Black, K. Choosing a combined oral contraceptive pill. Aust Prescr 2015; 38: 6–11.
Google Scholar | Crossref | Medline12. Fruzzetti, F, Trémollieres, F, Bitzer, J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol 2012; 28: 400–408.
Google Scholar | Crossref | Medline13. Wu, H-M, Chang, H-M, Leung, PCK. Gonadotropin-releasing hormone analogs: mechanisms of action and clinical applications in female reproduction. Front Neuroendocrinol. 2021; 60: 100876.
Google Scholar | Crossref | Medline14. Dinger, JC, Bardenheuer, K, Assmann, A. International active surveillance study of women taking oral contraceptives (INAS-OC Study). BMC Med Res Methodol 2009; 9: 77.
Google Scholar | Crossref | Medline15. Dinger, JC, Heinemann Lothar, AJ, et al. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007; 75: 344–354.
Google Scholar | Crossref | Medline16. Dinger, J, Do Minh, T, Heinemann, K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 2016; 94: 328–339.
Google Scholar | Crossref | Medline17. Dinger, J, Möhner, S, Heinemann, K. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives. Contraception 2016; 93: 378–385.
Google Scholar | Crossref | Medline18. Dinger, J, Minh, TD, Buttmann, N, et al. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011; 117: 33.
Google Scholar | Crossref | Medline19. Rothman, KJ, Poole, C. A strengthening programme for weak associations. Int J Epidemiol 1988; 17: 955–959.
Google Scholar | Crossref | Medline20. Guo, S, Frase, MW. Propensity score analysis: statistical methods and applications. (Advanced Quantitative Techniques in the Social Sciences, 11). 2nd ed. Los Angeles: Sage Publications Inc.
Google Scholar21. Rosenbaum, PR, Rubin, DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41–55.
Google Scholar | Crossref22. SAS Institute Inc . The SAS system for Windows. Cary, NC: SAS Institute Inc., 2013.
Google Scholar23. Kat, AC, de, Dam, V, Onland-Moret, NC, et al. Unraveling the associations of age and menopause with cardiovascular risk factors in a large population-based study. BMC Med 2017; 15: 2.
Google Scholar | Crossref | Medline24. Atsma, F, Bartelink, ML, Grobbee, DE, et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006; 13: 265–279.
Google Scholar | Crossref | Medline25. Kuh, D, Langenberg, C, Hardy, R, et al. Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British birth cohort study. BJOG 2005; 112: 476–485.
Google Scholar | Crossref | Medline26. As-Sanie, S, Becker, CM, Johnson, N, et al. Efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: phase 3 randomized, double-blind, placebo-controlled study (spirit 2). Fertil Steril 2020; 114: e77.
Google Scholar | Crossref | Medline27. Lamb, YN. Elagolix: first global approval. Drugs 2018; 78: 1501–1508.
Google Scholar | Crossref | Medline28. Pohl, O, Marchand, L, Fawkes, N, et al. Gonadotropin-releasing hormone receptor antagonist mono- and combination therapy with estradiol/norethindrone acetate add-back: pharmacodynamics and safety of OBE2109. J Clin Endocrinol Metab 2018; 103: 497–504.
Google Scholar | Crossref | Medline29. Schlaff, WD, Ackerman, RT, Al-Hendy, A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med 2020; 382: 328–340.
Google Scholar | Crossref | Medline30. Pohl, O, Marchand, L, Bell, D, et al. Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern. Reprod Sci 2020; 27: 988–995.
Google Scholar | Crossref | Medline31. Dinger, J, Möhner, S, Heinemann, K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol 2013; 122(4): 800–808.
Google Scholar | Crossref | Medline32. Junge, W, Mellinger, U, Parke, S, et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig 2011; 31: 573–584.
Google Scholar | Crossref | Medline33. Klipping, C, Duijkers, I, Parke, S, et al. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D 2011; 11: 159–170.
Google Scholar | Crossref | Medline34. Nelson, A, Parke, S, Mellinger, U, et al. Efficacy and safety of a combined oral contraceptive containing estradiol valerate/dienogest: results from a clinical study conducted in North America. J Womens Health (Larchmt) 2014; 23: 204–210.
Google Scholar | Crossref | Medline35. Risk Factors for Venous Thromboembolism (VTE) , https://www.heart.org/en/health-topics/venous-thromboembolism/risk-factors-for-venous-thromboembolism-vte (Accessed 24 July 2019).
Google Scholar36. Fewell, Z, Davey Smith, G, Sterne, JAC. The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. Am J Epidemiol 2007; 166: 646–655.
Google Scholar | Crossref | Medline37. Danziger, J, Zimolzak, AJ. Secondary analysis of electronic health records: residual confounding lurking in big data: a source of error. Cham, CH, Springer, 2016.
Google Scholar